| Theme |
PSC and PBC -- Recent Progress in Diagnosis and Treatment |
| Title |
Primary Sclerosing Cholangitis and Biliary Carcinoma |
| Author |
Kenji Hirano |
Department of Gastroenterology, Faculty of Medicine, University of Tokyo |
| Author |
Takeo Watanabe |
Department of Gastroenterology, Faculty of Medicine, University of Tokyo |
| Author |
Suguru Mizuno |
Department of Gastroenterology, Faculty of Medicine, University of Tokyo |
| Author |
Minoru Tada |
Department of Gastroenterology, Faculty of Medicine, University of Tokyo |
| Author |
Hiroyuki Isayama |
Department of Gastroenterology, Faculty of Medicine, University of Tokyo |
| Author |
Kazuhiko Koike |
Department of Gastroenterology, Faculty of Medicine, University of Tokyo |
| [ Summary ] |
It is known that primary sclerosing cholangitis (PSC) can be a risk factor for biliary carcinoma including extra- and intrahepatic cholangiocarcinoma (CCA) along with gallbladder carcinoma. In our series, biliary carcinoma occurred in 9 patients (CCA in 7 and gallbladder carcinoma in 2) during follow-ups on 54 patients. The mean period between the occurrence of PSC and biliary carcinoma was 61 months (2-152 months). The mean onset age was 43 years (22-63 years). In our analysis, association with inflammatory bowel disease and normal IgE levels were significant risk factors for biliary carcinoma in cases of PSC. The prognosis was generally poor. All 9 patients have already died. The mean survival period was 17 months (5-41 months). Four patients received surgical treatment, but recurrence was observed later in all cases. Measuring CA19-9 may be useful in the surveillance of biliary carcinoma, although results are not always conclusive. |